Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
Clinical trial NCT04923906 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04923906
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-11
- Primary completion
- 2024-06-18
- Enrollment
- 624
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.